Intrahepatic Cholangiocarcinoma: State of the Art of FGFR Inhibitors.

ABSTRACT:

Objective

Intrahepatic cholangiocarcinoma (iCCA), the second most common type of primary liver tumor, has an increasing incidence in the past few decades. iCCA is highly malignant, with a 5-year survival rate of approximately 5-10%. Surgical resection is usually the prescribed treatment for patients with early stage iCCA; however, patients are usually in an advanced stage iCCA upon diagnosis. Currently, targeted therapy combined with chemotherapy and other comprehensive treatment measures have been mainly adopted as palliative treatment measures. As a common candidate of targeted therapy, FGFR inhibitors have demonstrated their unique advantages in clinical trials. At present, the prospect of FGFR targeted therapy is encouraging. The landscape of FGFR inhibitors in iCCA is needed t

SUBMITTER: Wu T 

PROVIDER: S-EPMC8482710 | biostudies-literature | 2021 Jan-Dec

REPOSITORIES: biostudies-literature